A new Canadian study reports that dopamine agonist withdrawal syndrome (DAWS) is a potentially disabling complication associated with dopamine agonist use in patients with Parkinson’s disease (Pondal et al. J Neurol Neurosurg Psychiatry 2012; epublished August 29, 2012).